About Ikena Oncology

Ikena Oncology develops targeted therapies that focus on the Hippo and RAS signaling pathways to address cancer growth and resistance. Their biomarker-driven approach aims to provide effective treatment options for specific patient populations with high unmet medical needs.

```xml <problem> Approximately 30% of all human cancers are driven by mutations in the RAS pathway, but current therapies and product candidates do not address roughly 85% of these mutations. Many existing RAS pathway inhibitors are also limited by cancer cells' ability to develop therapeutic resistance through signaling bypass mechanisms. </problem> <solution> Ikena Oncology develops targeted oncology therapies focused on the RAS signaling pathway, employing a tumor-directed approach. Their lead development candidate, IK-595, is a MEK-RAF molecular glue that traps MEK and RAF in an inactive complex, inhibiting RAS signals more completely than existing inhibitors. By complexing the RAFs, including CRAF, IK-595 prevents a signaling bypass mechanism that cancer cells use to drive therapeutic resistance. Trapping CRAF in an inactive complex also prevents the kinase-independent anti-apoptotic function in RAS and RAF mutant cancers. IK-595 is designed as an oral therapy with a pharmacokinetic profile that aims for a superior therapeutic window. </solution> <features> - IK-595: MEK-RAF molecular glue development candidate - Traps MEK and RAF in an inactive complex - Inhibits RAS signals more completely than existing inhibitors - Complexes RAFs, including CRAF, to prevent signaling bypass - Prevents kinase-independent anti-apoptotic function in RAS and RAF mutant cancers - Oral therapy with a half-life enabling a potentially superior pharmacokinetic profile </features> <target_audience> The primary target audience includes patients with RAS and RAF altered cancers, as well as the physicians who treat them. </target_audience> ```

What does Ikena Oncology do?

When was Ikena Oncology founded?

Ikena Oncology was founded in 2016.

How much funding has Ikena Oncology raised?

Ikena Oncology has raised 75000000.

Founded

2016

Funding

75000000

Employees

23 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Ikena Oncology

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

ikenaoncology.com 10K+

Crunchbase

Founded 2016

Funding

Estimated Funding

$50M+

Team (20+)

No team information available.

Company Description

Problem

Approximately 30% of all human cancers are driven by mutations in the RAS pathway, but current therapies and product candidates do not address roughly 85% of these mutations. Many existing RAS pathway inhibitors are also limited by cancer cells' ability to develop therapeutic resistance through signaling bypass mechanisms.

Solution

Ikena Oncology develops targeted oncology therapies focused on the RAS signaling pathway, employing a tumor-directed approach. Their lead development candidate, IK-595, is a MEK-RAF molecular glue that traps MEK and RAF in an inactive complex, inhibiting RAS signals more completely than existing inhibitors. By complexing the RAFs, including CRAF, IK-595 prevents a signaling bypass mechanism that cancer cells use to drive therapeutic resistance. Trapping CRAF in an inactive complex also prevents the kinase-independent anti-apoptotic function in RAS and RAF mutant cancers. IK-595 is designed as an oral therapy with a pharmacokinetic profile that aims for a superior therapeutic window.

Features

IK-595: MEK-RAF molecular glue development candidate

Traps MEK and RAF in an inactive complex

Inhibits RAS signals more completely than existing inhibitors

Complexes RAFs, including CRAF, to prevent signaling bypass

Prevents kinase-independent anti-apoptotic function in RAS and RAF mutant cancers

Oral therapy with a half-life enabling a potentially superior pharmacokinetic profile

Target Audience

The primary target audience includes patients with RAS and RAF altered cancers, as well as the physicians who treat them.